Scholar Rock up after Biohaven SMA data disappoints

Shares of Scholar Rock (SRRK) are up $9.02, or 30%, to $38.94 in morning trading after rival Biohaven (BHVN) reported that taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale, but the treatment arm did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care group, in the RESILIENT SMA study. Previously, Scholar Rock hit on the primary endpoint in the company’s own Phase 3 trial of apitegromab in patients with SMA, or spinal muscular atrophy. In Monday morning trading, shares of Biohaven are off their earlier lows, trading fractionally above and below the stock’s prior day closing price.